Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 12 Carcinoma, Transitional Cell 7 Ureteral Neoplasms 4 Neoplasm Metastasis 3 Urethral Neoplasms 2 Urothelial Cancer 1 Urologic Neoplasms 1 Urogenital Neoplasms 1 Renal Insufficiency 1 Prostatic Neoplasms 1 Penile Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms 1 Locally Advanced or Metastatic Unresectable Urothelial Cancer 1 Kidney Neoplasms 1 Carcinoma 1

Interventions

Cisplatin 6 pembrolizumab 5 fludarabine 5 Nivolumab 5 Cyclophosphamide 5 aldesleukin 4 Paclitaxel 4 Magnetic Resonance Spectroscopy 4 Ifosfamide 4 Radiotherapy 3 Ipilimumab 3 fludarabine phosphate 2 entinostat 2 cabozantinib 2 avelumab 2 aflibercept 2 Specimen Handling 2 CTLA-4 Antigen 2 Biopsy 2 Adoptive Transfer 2 vinflunine 1 toripalimab 1 rocakinogene sifuplasmid 1 ripretinib 1 oncogene protein E7, Human papillomavirus type 16 1 niraparib 1 nimotuzumab 1 lenvatinib 1 enfortumab vedotin 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Penile Neoplasms × vinflunine × Genitourinary × Clear all

NCT02057913 2020-07-23

VinCaP

Institute of Cancer Research, United Kingdom

Phase 2 Completed

Penile Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡